Denied Antireflux Surgery Appeals: Outcomes

Surgical and endoscopic procedures for gastro-oesophageal reflux, reviewed against criteria that require documented medical therapy, objective testing and a defined symptom duration.

What the independent reviewers decided

39%

overturned by the independent reviewer

of 64 decisions in the corpus

Source

California DMHC independent medical review determinations, 2017-2026. Public record.

Read this as a base rate, not as your odds

These are decisions about other patients, in one state, that had already been through the plan's own internal appeal and were then sent to an outside reviewer. That population is self-selected toward disputes worth pursuing, so the rate says what happened to cases like this at that stage — not what will happen to a specific claim. It is not medical or legal advice.

Why plans deny antireflux procedure

The documented course of acid-suppression therapy is shorter than the policy requires.
Objective testing the policy names — pH study, manometry, endoscopy — is absent from the file.
Symptoms are characterised as controlled on medication, so surgery is read as elective.
The specific technique requested is treated as investigational by the policy.

What actually carried the cases that won

Failed conservative treatment led at 44%, with chronicity and functional impact level behind at 40% each. That balance describes what a winning file contained: a documented medical course that did not hold, a symptom history with a length to it, and a consequence the patient lives with. Objective testing mattered as the entry ticket rather than as the argument. Peer-reviewed literature was cited in 56% of the reversals, well ahead of clinical guidelines.

What the record showed	Share of overturned decisions
Conservative treatment was documented as failed	44%
The condition was documented as chronic or long-standing	40%
The functional impact on the patient was documented	40%
A published guideline supported the request	40%
The severity or urgency was documented	40%
Objective findings were documented	24%
The diagnosis was confirmed	12%
Prior treatment was documented	8%

Shares are of the overturned decisions and do not sum to 100% — a single decision often rested on more than one, and some rested on none of these.

What the reviewers cited

Peer-reviewed literature — in 56% of the overturned decisions
Clinical guidelines — in 28% of the overturned decisions
FDA labeling — in 16% of the overturned decisions
Specialty-society criteria — in 16% of the overturned decisions

antireflux procedure denials — frequently asked

Is a denied antireflux procedure worth appealing?

Most of these held for the plan — 39 upheld against 25 reversed, across 64 California determinations. These denials held up more often than they fell.

What does 'failed medical therapy' have to show?

Agents, doses, durations and what happened. Failed conservative treatment appeared in 44% of the reversals, and a policy that names a minimum course will read an unquantified statement of failure as not meeting it.

Is objective testing required?

Where the policy names it, its absence is a clean basis for denial regardless of the clinical picture. Supplying the study is usually faster than arguing it should not be required.

Source

California Department of Managed Health Care — independent medical review determinations

Denial reasons and criteria are described in plain language for reference and vary by plan and policy. This page reports what independent reviewers decided in a public California dataset; it is general information, not medical, legal, or coverage advice.

When the appeal has to be written, and cited

Upload the denied EOB and Merits returns a complete, citation-verified appeal letter — the clinical argument, the payer's own coverage criteria, and your federal appeal rights — in about a minute.

Appeal a denial →